title: Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease.
abstract: BACKGROUND
  Low levels of free activated coagulation factor VII (VIIa) are normally present in plasma to prime the coagulation of blood in normal hemostasis and during thrombus formation. VIIa also circulates in inactive form, in complex with antithrombin (VIIaAT) formed when VIIa is bound to tissue factor (TF). This study evaluated VIIaAT in relation to cardiovascular disease (CVD).
  
  
  METHODS
  We determined the plasma VIIaAT concentration in samples from the Stockholm Coronary Atherosclerosis Risk Factor (SCARF) study, a population-based case-control study of myocardial infarction (MI) and in samples from the Stockholm study of 60-years-old individuals, a prospective study of CVD. VIIaAT was measured with a sandwich ELISA that captures the complex between a monoclonal antibody to VIIa and a polyclonal antibody to AT.
  
  
  RESULTS
  In the SCARF study (200 post-MI cases, 340 controls), VIIaAT was statistically significantly associated with patient status [odds ratio (95% confidence interval (CI)] 1.51 (1.09-2.08), p=0.0126). The case-control differences were however small, with VIIaAT values that largely overlap between the two groups. When a nested case-control design (211 incident CVD cases and 633 matched controls) was applied on 5- to 7-year follow-up results of the Stockholm prospective study of 60-year-olds, plasma VIIaAT concentration was not associated with incident CVD (odds ratio (95% CI) 1.001 (0.997-1.005), p=0.5447).
  
  
  CONCLUSIONS
  Plasma VIIaAT concentration had no predictive value for future CVD in our study population. Slightly increased plasma VIIaAT concentrations observed after MI may reflect processes that occur in connection with the acute event when TF and VIIa availability is increased.
authors.affiliation: Cardiovascular Genetics Group, Atherosclerosis Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Angela.Silveira@ki.se
authors.forename: Angela
authors.initials: A
authors.lastname: Silveira
authors.forename: Daniela
authors.initials: D
authors.lastname: Scanavini
authors.forename: Susanna
authors.initials: S
authors.lastname: Boquist
authors.forename: Carl-Göran
authors.initials: CG
authors.lastname: Ericsson
authors.forename: Mai-Lis
authors.initials: ML
authors.lastname: Hellénius
authors.forename: Karin
authors.initials: K
authors.lastname: Leander
authors.forename: Ulf
authors.initials: U
authors.lastname: de Faire
authors.forename: John
authors.initials: J
authors.lastname: Ohrvik
authors.forename: Barry
authors.initials: B
authors.lastname: Woodhams
authors.forename: James H
authors.initials: JH
authors.lastname: Morrissey
authors.forename: Anders
authors.initials: A
authors.lastname: Hamsten
mesh_terms: D058833:Antithrombin Proteins / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology / Q000378:metabolism; D016022:Case-Control Studies; D015942:Factor VIIa / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology / Q000378:metabolism; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D058833:Antithrombin Proteins; D015942:Factor VIIa